Plant Name: Ardisia neriifolia
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NMUR2; | |
| ADORA3; ADORA2A; ADORA1; ADRA2C; ADRA2A; | |
| PTPN1; | |
| ALPI; RECQL; TDP1; PLA2G2A; ADK; GLO1; CBR1; AKR1B1; HSD17B10; ALOX12; AKR1B10; ALOX15; NOX4; TNKS; PARP1; TNKS2; CD38; POLB; | |
| GAA; ACHE; | |
| TRPA1; | |
| GSK3B; FLT3; MAPK1; CDK6; | |
| CA2; CA1; CA12; CA9; CA7; CA3; CA14; CA5B; CA5A; CA4; CA6; | |
| ALOX5; PTGS1; MAOA; XDH; | |
| KDM4E; | |
| MMP9; MMP1; MMP12; MMP2; | |
| HIF1A; TP53; NFKB1; STAT6; | |
| ABCG2; ABCC1; | |
| SLC28A2; SLC28A3; SLC28A1; SLCO1B3; SLCO1B1; | |
| L3MBTL1; SMN1;SMN2; | |
| LMNA; MAPT; APP; TTR; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PLA2G2A | Phospholipase A2 group IIA | P14555 | CHEMBL3474 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.609E-12 | 1.009E-08 | ALPI, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, GLO1, L3MBTL1, MMP1, MMP12, MMP2, MMP9, PARP1, PTPN1, TNKS, TP53 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 9.345E-12 | 1.272E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.297E-11 | 4.924E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.338E-10 | 2.121E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.300E-09 | 1.518E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.667E-09 | 2.282E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.824E-08 | 8.825E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.997E-08 | 1.356E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 5.253E-08 | 2.200E-05 | ADORA1, ADORA2A, ADRA2A, CA2, CA7, CD38, CDK6, HIF1A, MAPK1, PARP1, TNKS, TNKS2, TRPA1 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 6.037E-08 | 2.390E-05 | ABCC1, ADORA1, ADRA2A, CA2, CA4, CA9, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.188E-07 | 4.241E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.526E-07 | 8.090E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.242E-06 | 3.173E-04 | ABCG2, ACHE, ADORA2A, ADRA2A, ADRA2C, APP, CD38, FLT3, L3MBTL1, MAPK1, MAPT, MMP9, NFKB1, PARP1, SMN1, SMN2, STAT6, TP53, TRPA1, TTR, XDH |
| BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 1.877E-06 | 4.256E-04 | ADORA1, ADRA2A, CD38, PARP1, TNKS, TNKS2, TRPA1 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 2.191E-06 | 4.633E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 4.921E-06 | 9.400E-04 | AKR1B1, CYP19A1, CYP1A1, CYP1B1, CYP3A4, TTR |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 4.921E-06 | 9.400E-04 | AKR1B1, CYP1B1, MAPK1, MMP9, STAT6, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 5.229E-06 | 9.731E-04 | ADORA2A, APP, MAPT |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 5.229E-06 | 9.731E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 7.125E-06 | 1.251E-03 | ABCC1, ALOX12, ALOX15, ALOX5 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 9.780E-06 | 1.633E-03 | ADORA1, CD38, CYP1A1, HIF1A, LMNA, MMP2, NOX4, TP53 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.358E-05 | 2.127E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 1.610E-05 | 2.337E-03 | SLC28A2, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.610E-05 | 2.337E-03 | ALOX12, ALOX15 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 1.610E-05 | 2.337E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.610E-05 | 2.337E-03 | ALOX12, ALOX15 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 1.610E-05 | 2.337E-03 | SLC28A2, SLC28A3 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.760E-05 | 2.537E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0051179; localization | GO:0051222; positive regulation of protein transport | 2.309E-05 | 3.182E-03 | ACHE, ADORA2A, APP, CD38, GSK3B, HIF1A, MAPK1, MMP12, PARP1, TP53 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.544E-05 | 3.440E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.415E-05 | 4.299E-03 | ALOX12, ALOX15, ALOX5 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 3.415E-05 | 4.299E-03 | ADORA1, ADORA2A, MAPT |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 3.571E-05 | 4.412E-03 | ADORA2A, CA2, CA7, HIF1A, MAPK1, TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 3.586E-05 | 4.412E-03 | ADORA1, ADORA2A, AKR1B1, ALOX12, CD38, GLO1, GSK3B, HIF1A, LMNA, MMP9, NFKB1, PTPN1, TP53 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 4.135E-05 | 4.975E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 4.817E-05 | 5.406E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.817E-05 | 5.406E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 4.817E-05 | 5.406E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.817E-05 | 5.406E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 4.817E-05 | 5.406E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 4.817E-05 | 5.406E-03 | ADRA2A, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 4.817E-05 | 5.406E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 4.817E-05 | 5.406E-03 | ADORA1, ADORA2A |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 5.237E-05 | 5.789E-03 | ABCG2, APP, CA12, CA2, CA7, CD38, HIF1A, MAPK1, NMUR2, TP53, TRPA1 |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 6.675E-05 | 7.090E-03 | NOX4, PARP1, POLB, TP53 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 6.951E-05 | 7.277E-03 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 7.471E-05 | 7.710E-03 | ACHE, AKR1B1, ALOX12, ALOX15, ALPI, CYP19A1, CYP1A1, CYP3A4, PLA2G2A, PTGS1 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 7.598E-05 | 7.767E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 7.995E-05 | 8.135E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 9.187E-05 | 9.304E-03 | ABCG2, APP, CA2, CA7, CD38, HIF1A, MAPK1, NMUR2, TP53, TRPA1 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 9.608E-05 | 9.382E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 9.608E-05 | 9.382E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 9.608E-05 | 9.382E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 9.608E-05 | 9.382E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0032795; heterotrimeric G-protein binding | 9.608E-05 | 9.382E-03 | ADORA1, ADRA2A |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.005E-24 | 6.543E-20 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.539E-17 | 8.379E-14 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.480E-16 | 6.010E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.847E-23 | 3.251E-21 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.057E-10 | 9.298E-09 | CYP2C9; CBR1; ALOX5; PLA2G2A; ALOX15; ALOX12; CYP2C19; PTGS1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.163E-10 | 3.029E-08 | CYP2C9; APP; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 6.625E-09 | 2.332E-07 | CBR1; MAOA; GAA; PLA2G2A; ALOX15; ADK; AKR1B1; ALOX12; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; CYP2C9; AKR1B10; ALOX5; CYP1A2; CYP1A1; CD38; ALPI; XDH |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.279E-09 | 5.629E-08 | CYP2C9; PLA2G2A; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.135E-08 | 9.196E-07 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.002E-07 | 1.006E-05 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.209E-06 | 5.648E-05 | GSK3B; CDK6; FLT3; MMP1; MMP2; MAPK1; HIF1A; TP53; MMP9; NFKB1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.319E-07 | 1.170E-05 | MMP1; MMP2; MAPK1; MMP9; TP53 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.089E-06 | 5.648E-05 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.327E-06 | 1.090E-04 | CYP2C9; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 7.429E-06 | 1.090E-04 | ABCC1; ADORA3; ADORA1; MAPK1; TP53; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.276E-05 | 2.670E-04 | CDK6; MAPK1; STAT6; TP53; MMP9; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 8.436E-06 | 1.142E-04 | SLCO1B1; CA2; SLCO1B3; CYP3A4; ABCG2 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.758E-05 | 2.210E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.035E-04 | 1.071E-03 | ADORA2A; ADORA3; ADORA1; NMUR2; ADRA2C; ADRA2A; TSHR |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.302E-05 | 4.732E-04 | ALOX5; CYP1A1; CYP1B1; CYP19A1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.592E-04 | 1.274E-03 | ABCC1; CDK6; CYP1B1; MAPK1; TP53; MMP9; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.284E-04 | 1.190E-03 | CDK6; MAPK1; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.192E-04 | 1.543E-03 | PARP1; LMNA; MAPK1; TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.210E-04 | 1.183E-03 | CYP2C9; CYP1A2; CYP1A1; CYP3A4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.362E-04 | 1.198E-03 | FLT3; MAPK1; TP53; HIF1A |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.900E-04 | 1.454E-03 | CDK6; MAPK1; TP53; NFKB1 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 4.936E-04 | 3.188E-03 | ADORA3; ADORA1; MAPK1; ADRA2C; ADRA2A |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.065E-04 | 2.752E-03 | GSK3B; MAPK1; TP53; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 5.072E-04 | 3.188E-03 | APP; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.087E-03 | 6.448E-03 | ADORA2A; ADORA1; MAPK1; NFKB1; TSHR |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.188E-03 | 6.463E-03 | MMP2; MAPK1; TP53; HIF1A; MMP9 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.241E-03 | 6.463E-03 | POLB; CDK6; MAPK1; TP53; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.173E-03 | 6.463E-03 | GSK3B; MAPK1; TP53; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.249E-03 | 6.463E-03 | GSK3B; MAPK1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.823E-03 | 8.254E-03 | GSK3B; MAPK1; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.977E-03 | 8.700E-03 | GSK3B; CDK6; TP53; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.099E-03 | 6.448E-03 | GSK3B; MAPK1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.363E-03 | 6.665E-03 | CDK6; MAPK1; TP53 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.363E-03 | 6.665E-03 | ADORA1; TSHR; PTGS1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.435E-03 | 6.826E-03 | FLT3; MAPK1; NFKB1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.095E-03 | 8.993E-03 | CDK6; MAPK1; TP53 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 5.394E-03 | 2.020E-02 | FLT3; TP53; MMP9; NFKB1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.696E-03 | 1.130E-02 | CDK6; MAPK1; TP53 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.805E-03 | 1.148E-02 | GSK3B; MAPK1; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.917E-03 | 1.167E-02 | GSK3B; MAPK1; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.829E-03 | 8.254E-03 | GSK3B; MAPK1; TP53 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 7.231E-03 | 2.434E-02 | MMP2; MAPK1; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 8.053E-03 | 2.531E-02 | GSK3B; CD38; TP53; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 6.843E-03 | 2.383E-02 | MMP2; MAPK1; MMP9 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 4.629E-03 | 1.771E-02 | CDK6; TP53; NFKB1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.148E-04 | 1.543E-03 | AKR1B10; GAA; AKR1B1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.071E-02 | 3.142E-02 | GSK3B; CDK6; MAPK1; TP53; NFKB1 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 6.286E-03 | 2.258E-02 | CA2; PLA2G2A; CD38 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 7.631E-03 | 2.487E-02 | MAPK1; HIF1A; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 7.836E-03 | 2.507E-02 | GSK3B; MAPK1; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 9.133E-03 | 2.725E-02 | MAPK1; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 8.909E-03 | 2.703E-02 | PTPN1; GSK3B; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.765E-02 | 4.567E-02 | MAPK1; MAPT; TP53; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.105E-02 | 3.188E-02 | ALOX5; MAPK1; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.834E-02 | 4.677E-02 | POLB; GSK3B; TP53; NFKB1 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 1.156E-02 | 3.282E-02 | ADORA2A; PLA2G2A; MAPK1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.263E-02 | 3.514E-02 | GSK3B; CDK6; TP53 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.711E-02 | 4.494E-02 | PTPN1; GSK3B; MAPK1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.951E-02 | 4.906E-02 | GSK3B; TP53 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.569E-02 | 4.183E-02 | MAOA; NFKB1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 5.694E-03 | 2.088E-02 | MAPK1; TP53 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.391E-02 | 3.766E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.278E-02 | 3.514E-02 | ABCC1; ABCG2 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 6.904E-03 | 2.383E-02 | AKR1B10; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 7.331E-03 | 2.434E-02 | POLB; PARP1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 8.682E-03 | 2.681E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.602E-03 | 1.409E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.490E-04 | 1.249E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADORA2A; CA1; CA1; AKR1B1; ADORA1; ADRA2C; ACHE |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1 |
| NA: NA | GIST | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; ADORA1; ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; ACHE; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA2A; ADORA1; MAOA; PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| C00-D49: Neoplasms | Melanoma | C43 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; PTGS1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; MAOA; ACHE |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; MMP1; ABCC1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; ADORA2A; ADORA1; ADRA2C; MMP12; CBR1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2; PTGS1 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; PARP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; MAOA |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| C00-D49: Neoplasms | Ovarian cancer | C56 | PARP1; MMP2 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1; ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADK; ADORA2A; ADRA2C; ADRA2A; TRPA1; ACHE; PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA2A; ADORA1; MAOA; ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; GSK3B; AKR1B1; ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; FLT3; FLT3; CA9; PLA2G2A |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| C00-D49: Neoplasms | Cancer | C00-C96 | GSK3B; ADORA3; HIF1A; TP53; CA1; FLT3; FLT3; CA9; MAPK1; MMP9; NFKB1; PARP1; MMP2; ACHE; CD38; APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Multiple myeloma | C90 | CD38 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; CD38 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; MAOA; ADRA2C; ACHE; ACHE; ACHE; MAPT; APP |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; ADORA1 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; ADRA2C |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; PTGS1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9; PTGS1 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; ADORA2A; MMP12; MMP12 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; MMP1; AKR1B1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; FLT3; CA9; MAPK1; MMP9; MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; MMP12; PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1 |